The effectiveness of preventive use of partially hydrolyzed dietary fibers of cyamopsis tetrahedral (OptiFibre®) in patients with benign prostatic hyperplasia and chronic functional constipation

Cover Page

Cite item

Full Text

Abstract

Anatomical proximity of the prostate gland and colon, common innervation, blood and lymph circulation create prerequisites for the involvement of the intestine in the pathological process in prostate diseases.

Aim To evaluate the effectiveness of preventive treatment of chronic constipation (CC) with the use of partially hydrolyzed dietary fibers of cyamopsis tetrahedral (OptiFiber®) in patients with benign prostatic hyperplasia (BPH) who are shown to have a prostate tour and its effect on the course of the postoperative period.

Materials and methods. We examined 60 patients with BPH who were referred for surgical treatment (transurethral resection of the prostate), who had chronic functional constipation. By random sampling, the patients were divided into two groups of 30 people. In group 1, standard preparation for surgical treatment was carried out for 1 month. In group 2, patients, in combination with standard preparation for surgical treatment, took partially hydrolyzed dietary fibers of cyamopsis tetrahedral (OptiFiber®) with food for the first 3 days – 1 sachet (5 g) per day, from the 4th to the 6th day – 2 sachets per day. From day 7, patients in group 2 were divided into two subgroups. In subgroup 2a, patients whose bowel function returned to normal continued taking the drug at a dose of 2 sachets per day. Those patients in whom the effect of restoring the regularity of bowel function was not satisfactory, took 3 sachets a day from the 7th day and were assigned to subgroup 2b. In the preoperative period, patients were examined on the 1st day (visit 1), 15th day (visit 2) and 30th day (visit 3) of observation. The average number of acts of defecation during the previous week, the severity and dynamics of clinical manifestations of constipation were evaluated on the basis of the Patient Assessment of Constipation Symptoms (PAC-SYM questionnaire), according to the totality of symptoms in points, as well as for each criterion separately. Evaluation of the effectiveness of treatment in the postoperative period was carried out on the basis of dynamic observation for 5–7 days.

Results. Initially, all patients in the two groups had signs characteristic of BPH and chronic functional constipation, the groups were homogeneous. According to the results obtained in group 1 for 30 days of follow-up before surgery, none of the studied parameters significantly changed (p>0.05). In group 2, after 15 days of follow-up, a significant (p<0.05) positive dynamics was revealed for all the studied indicators, both in comparison with group 1 and in comparison with the results obtained at visit 1. By visit 3, despite the absence of statistically significant dynamics in the indicators of both group 1 and group 2, in comparison with visit 2, significant (p<0.05) differences remained between the groups. During the study, subgroup 2a included 19 patients who took 2 sachets of OptiFiber® per day, and subgroup 2b included 11 men who took 3 sachets per day from the 7th day of observation. Restoration of intestinal motility in patients taking dietary fiber occurred at an earlier time, while the differences were also statistically significant (p<0.05). In group 1, 14 cases of early postoperative complications were registered, and in group 2–9 cases, which is 35.7% less. The number of cases of antibiotic-associated diarrhea in group 1 was 3, while in group 2 there was 1 such case, which is 66.7% less. When analyzing the results obtained, there were no significant differences in the studied parameters in the postoperative period between subgroups 2a and 2b. All 30 (100%) patients of group 2 gave a positive review of partially hydrolyzed dietary fibers of cyamopsis tetrahedral (OptiFiber®), and plan to continue taking them after completing participation in the study.

Conclusion. Thus, according to the results of the study, we consider it appropriate to use partially hydrolyzed dietary fibers of cyamopsis tetrahedral (OptiFiber®) in the treatment of CC in patients with BPH who are shown to have a prostate tour as a means to effectively eliminate the manifestations of CC, improve the results of surgical treatment and improve the quality of life of this category of patients.

About the authors

Andrey V. Kuzmenko

Burdenko Voronezh State Medical University

Author for correspondence.
Email: Kuzmenkoav09@yandex.ru
ORCID iD: 0000-0002-7927-7015

D. Sci. (Med.), Prof.

Russian Federation, Voronezh

Vladimir V. Kuzmenko

Burdenko Voronezh State Medical University

Email: vvkuzmenko2003@mail.ru
ORCID iD: 0000-0001-7803-8832

D. Sci. (Med.), Prof.

Russian Federation, Voronezh

Timur A. Gyaurgiev

Burdenko Voronezh State Medical University

Email: GTA001100@yandex.ru
ORCID iD: 0000-0002-2209-6264

Cand. Sci. (Med.)

Russian Federation, Voronezh

References

  1. Урология. Российские клинические рекомендации. Под ред. Ю.Г. Аляева, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа, 2018 [Urologiia. Rossiiskie klinicheskie rekomendatsii. Pod red. IuG Aliaeva, PV Glybochko, DIu Pushkaria. Moscow: GEOTAR-Media, 2018 (in Russian)].
  2. Российское общество урологов. Федеральные клинические рекомендации. Доброкачественная гиперплазия предстательной железы – 2020 [Rossiiskoe obshchestvo urologov. Federal'nye klinicheskie rekomendatsii. Dobrokachestvennaia giperplaziia predstatel'noi zhelezy – 2020 (in Russian)].
  3. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam 2022.
  4. Nickel JC. Prostatitis. Can Urol Assoc J. 2011;5(5):306-15. doi: 10.5489/cuaj.11211
  5. Schaeffer AJ. Classification (Traditional and National Institutes of Health) and Demographics of Prostatitis. Urology. 2002;60(6 Suppl.):5-6;discussion 6-7. doi: 10.1016/s0090-4295(02)02292-6
  6. Roehrborn CG. Benign Prostatic Hyperplasia: Etiology, Pathophysiology, Epidemiology, and Natural History. Campbell-Walsh Urology. 2012:2570-610.e10. doi: 10.1016/b978-1-4160-6911-9.00091-8
  7. Gupta N, Rogers T, Holland B, et al. Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial. J Urol. 2018;200(2):405-13. doi: 10.1016/j.juro.2018.02.3088
  8. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Кузьменко Г.А. Оценка отдаленных результатов применения энтомологического препарата в комплексной терапии пациентов с доброкачественной гиперплазией предстательной железы и хроническим простатитом. Урология. 2022;6:30-5 [Kuzmenko AV, Kuzmenko VV, Gyaurgiev TA, Kuzmenko GA. Evaluation of long-term results of the use of entomological drug in the combination therapy of patients with benign prostatic hyperplasia and chronic prostatitis. Urologiia. 2022;6:30-5 (in Russian)]. doi: 10.18565/urology.2022.6.30-35
  9. Кудрявцев Ю.В., Сивков А.В. Морфологические изменения ткани предстательной железы при доброкачественной гиперплазии. Экспериментальная и клиническая урология. 2010;1:18-22 [Kudryavcev YuV, Sivkov AV. Morphological alteration in benign prostatic hyperplasia tissue. Experimental and Clinical Urology. 2010;1:18-22 (in Russian)].
  10. Кузьменко А.В., Гяургиев Т.А., Баранников И.И., Лейбович Б.Е. Хронобиологический подход к лечению больных доброкачественной гиперплазией предстательной железы и хроническим простатитом: результаты морфологического исследования. Урологические ведомости. 2021;11(2):113-22 [Kuzmenko AV, Gyaurgiev TA, Barannikov II, Leybovich BE. Chronobiological approach to the treatment of patients with benign prostate hyperplasia and chronic prostatitis: results of a morphological examination. Urologicheskie vedomosti. 2021;11(2):113-22 (in Russian)]. doi: 10.17816/uroved56807
  11. Bartoletti R, Cai T, Mondaini N, et al. Prevalence, incidence estimation, risk factors and characterization of chronic prostatitis/chronic pelvic pain syndrome in urological hospital outpatients in Italy: results of a multi-center case-control observational study. J Urol. 2007;178(6):2411-5;discussion 2415. doi: 10.1016/j.juro.2007.08.046
  12. Huang XH, Qin B, Liang YW. LUTS in BPH patients with histological prostatitis before and after transurethral resection of the prostate. Zhonghua Nan Ke Xue. 2013;19(1):35-9.
  13. Hunt RH, Tougas G. Evolving concepts in functional gastrointestinal disorders: promising directions for novel pharmaceutical treatments. Best Pract Res Clin Gastroenterol. 2002;16(6):869-83. doi: 10.1053/bega.2002.0356
  14. Попков В.М. Клинико-диагностическое значение изменений толстой кишки при хроническом простатите. Саратовский научно-медицинский журнал. 2010;6(2):453-57 [Popkov VM. Clinical and diagnostic importance of changes of colon at chronic prostatitis. Saratov Journal of Medical Scientific Research. 2010;6(2):453-57 (in Russian)].
  15. Глыбочко П.В., Попков В.М., Блюмберг Б.И. Колоректальная патология как клиническая маска хронического простатита. Курский научно-практический вестник «Человек и его здоровье». 2010;2:59-63 [Glybochko PV, Popkov VM, Blyumberg BI. Colorectal pathology as a clinical mask of chronic prostatitis. Kurskii nauchno-prakticheskii vestnik «Chelovek i ego zdorov'e». 2010;2:59-63 (in Russian)].
  16. Ивашкин В.Т., Маев И.В., Шептулин А.А., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению взрослых пациентов с хроническим запором. Рос журн гастроэнтерол гепатол колопроктол. 2017;27(3):75-83 [Ivashkin VT, Mayev IV, Sheptulin AA. Diagnostics and treatment of chronic constipation in adults: clinical guidelines of the Russian gastroenterological association. Ross z gastroenterol gepatol koloproktol. 2017;27(3):75-83 (in Russian)]. doi: 10.22416/1382-4376-2017-27-3-75-83
  17. Минушкин Н.А. Функциональный запор: рекомендации по диагностике и лечению. РМЖ. Гастроэнтерология. 2016;11:703-7 [Minushkin ON. Functional constipation: diagnostic and treatment recommendations. RMJ. Gastroenterology. 2016;11:703-7 (in Russian)].
  18. Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33(8):895-901. doi: 10.1111/j.1365-2036.2011.04602.x
  19. Нестеров С.Н., Ханалиев Б.В., Бонецкий Б.А., и др. Лечение инфекционно-воспалительных осложнений после трансуретральной резекции предстательной железы. Вестник Национального медико-хирургического Центра им. Н.И. Пирогова. 2018;13(2):169-170 [Nesterov SN, Hanaliev BV, Bonetsky BA. Treatment of infectious inflammatory complications after transurethral resection of the prostate. Vestnik Natsional'nogo mediko-khirurgicheskogo Tsentra im. N.I. Pirogova. 2018;13(2):169-170 (in Russian)].
  20. Мартов А.Г., Меринов Д.С., Корниенко С.И., и др. Послеоперационные урологические осложнения трансуретральных электрохирургических вмешательств на предстательной железе по поводу аденомы. Урология. 2006;2:25-32 [Martov AG, Merinov DS, Kornienko SI. Postoperative urological complications of transurethral electrosurgical interventions on the prostate for adenoma. Urologiia. 2006;2:25-32 (in Russian)].
  21. Mebust WK, Holtgrewe HL, Cockett AT. Transurethral prostatectomy: immediate and postoperative complications. Cooperative study of 13 participating in stitutions evaluating 3,885 patients. J Urol. 2002;167(1):5-9. doi: 10.1016/s0022-5347(05)65370-0
  22. Фомин В.С., Ветшев Ф.П. Консервативная коррекция моторно-эвакуаторных нарушений в послеоперационном периоде (обзор литературы). Фарматека. 2019;26(2):20-4 [Fomin VS, Vetshev FP. Conservative correction of motor-evacuation disorders in the postoperative period (literature review). Farmateka. 2019;26(2):20-4 (in Russian)]. doi: 10.18565/pharmateca.2019.2.20-24
  23. Евсеев М.А., Фомин В.С., Никитин В.Е. Патогенетические аспекты развития синдрома энтеральной недостаточности в послеоперационном периоде. Анналы хирургии. 2018;23(1):5-13 [Evseev MA, Fomin VS, Nikitin VE. Pathogenetic aspects of enteric insufficiency in the postoperative period. Annaly Khirurgii (Russian Journal of Surgery). 2018;23(1):5-13 (in Russian)]. doi: 10.18821/1560-9502-2018-23-1-5-13
  24. Белик Б.М., Ковалев А.Н. Современный подход к выбору слабительного средства при хирургических вмешательствах в амбулаторной колопроктологии. Амбулаторная хирургия. 2022;19(2):96-105 [Belik BM, Kovalev AN. Modern approach to the choice of laxative agent in surgical interventions in outpatient coloproctology. Ambulatornaya khirurgiya = Ambulatory Surgery. 2022;19(2):96-105 (in Russian)]. doi: 10.21518/1995-1477-2022-19-2-96-105
  25. Tsuchie SY, Nani FS, Vieira JE. Incidence of postoperative dyspepsia is not associated with prophylactic use of drugs. Sao Paulo Med J. 2014;132(4):219-23. doi: 10.1590/1516-3180.2014.1324676
  26. Takahashi H, Wako N, Okubo T, et al. Influence of partially hydrolyzed guar gum on constipation in women. J Nutr Sci Vitaminol (Tokyo). 1994;40(3):251-9. doi: 10.3177/jnsv.40.251
  27. Russo L, Andreozzi P, Zito FP, et al. Partially hydrolyzed guar gum in the treatment of irritable bowel syndrome with constipation: effects of gender, age, and body mass index. Saudi J Gastroenterol. 2015;21(2):104-10. doi: 10.4103/1319-3767.153835
  28. Бордин Д.С., Кучерявый Ю.А., Андреев Д.Н. Хронический запор: актуальность проблемы и современные возможности терапии. Эффективная фармакотерапия. 2019;15(36):76-80 [Bordin DS, Kucheryavy YuA, Andreyev DN. Chronic Сonstipation: Urgency of the Problem and Modern Possibilities of Therapy. Effective Pharmacotherapy. 2019;15(36):76-80 (in Russian)]. doi: 10.33978/2307-3586-2019-15-36-76-80
  29. Ардатская М.Д. Роль пищевых волокон в коррекции нарушений микробиоты и поддержании иммунитета. РМЖ. 2020;12:24-9 [Ardatskaya MD. Role of dietary fiber in correcting microbiota disorders and maintaining immunity. RMJ. 2020;12:24-9 (in Russian)].
  30. Ардатская М.Д. Роль пищевых волокон в коррекции нарушений микробиоценоза кишечника на фоне антибактериальной терапии. Эффективная фармакотерапия. 2021;17(28):46-52 [Ardatskaya MD. Role of Dietary Fiber in the Correction of Gut Microbiocenosis Disorders Against the Background of Antibacterial Therapy. Effective Pharmacotherapy. 2021;17(28):46-52 (in Russian)].

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies